Two revolutionary new cancer therapies that use genetic engineering to treat acute lymphoblastic leukemia (ALL) and certain types of lymphoma are going to rely on the expertise of oncology departments at health systems, with pharmacies playing key roles in providing ongoing supportive patient care, according to experts.
The new treatments—chimeric antigen receptor (CAR) T-cell immunotherapies—consist of autologous T cells that are sent to a manufacturing center and genetically